ICAM-1 Antisense Oligonucleotide for Radiation Proctitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Radiation Induced Proctitis, a side effect of pelvic radiation therapy, are inadequate, causing persistent bleeding, inflammation, and quality of life issues, with limited effectiveness of existing therapies like thermal therapy and medications.
Innovation Solution
A composition comprising an ICAM-1 antisense oligonucleotide with a specific nucleic acid sequence (SEQ ID NO:1) is used to treat Radiation Induced Proctitis, delaying, reducing, or ameliorating symptoms such as rectal bleeding, diarrhea, and pain, by specifically hybridizing to the 3′-untranslated region of human ICAM-1 mRNA, and can be administered via various routes including rectal enemas.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If thermal therapy is used to stop bleeding and inflammation, then the severity of symptoms is reduced, but the invasiveness and patient discomfort increase
Solution Approach 1:
The patent replaces mechanical thermal therapy with a biochemical mechanism using antisense oligonucleotides that bind to ICAM-1 mRNA to prevent protein synthesis, thereby treating radiation proctitis through molecular biology rather than thermal/mechanical intervention
Solution Approach 2:
The antisense oligonucleotide acts as an intermediary molecule that specifically binds to ICAM-1 mRNA, preventing the translation of the ICAM-1 protein and thereby reducing inflammation and bleeding without requiring invasive thermal procedures
2Object-affected harmful factors
If sucralfate, 5-ASA or corticosteroid enemas are used, then pain and inflammation are reduced, but the effectiveness is limited
Solution Approach 1:
The patent extracts and targets the specific molecular cause of radiation proctitis by designing an antisense oligonucleotide that specifically binds to ICAM-1 mRNA, removing the pathogenic mechanism at its source rather than providing general anti-inflammatory coverage
Solution Approach 2:
The antisense oligonucleotide provides localized and specific action at the molecular level by binding exclusively to ICAM-1 mRNA sequences, creating a targeted therapeutic effect that addresses the specific pathogenic mechanism without the broad, less effective coverage of conventional enemas
3Object-affected harmful factors
If multiple thermal therapy treatments are required, then the bleeding and inflammation are controlled, but the treatment complexity and patient burden increase
Solution Approach 1:
The antisense oligonucleotide is administered in advance to prevent the expression of ICAM-1 protein, thereby preventing the development of radiation proctitis symptoms before they occur, rather than requiring multiple subsequent treatments to control established symptoms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oligonucleotide effectively reduces inflammation, pain, and discharge associated with Radiation Induced Proctitis, offering a therapeutically effective treatment option with potential for long-term symptom remission and improved patient compliance.
Implementation Method 1
SEQ ID NO:1 is a 20-base phosphorothioate oligodeoxynucleotide designed to specifically hybridize to a sequence in the 3′-untranslated region of the human ICAM-1 mRNA
Data Source
AI summary
This invention relates to a composition comprising an antisense oligonucleotide for use in treating radiation induced disease of the gastrointestinal tract.